Spots Global Cancer Trial Database for RWD Study in HER2+ mBC Patients in Third-Line Therapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: RWD Study in HER2+ mBC Patients in Third-Line Therapy

Official Title: Real-World Data Study in HER2+ Metastatic Breast Cancer Patients in Third-Line Therapy

Study ID: NCT04566458

Conditions

Breast Cancer Stage IV

Interventions

No intervention

Study Description

Brief Summary: This retrospective observational study will collect Canadian real-world data (RWD) from HER2+ metastatic breast cancer (mBC) patients to describe treatment sequences of all therapies received in the metastatic setting, to measure overall survival (OS), progression free survival (PFS), time to next active anti-cancer therapy, and to estimate the health resources utilization (HRU) during third-line therapy.

Detailed Description: The proportion of treatment received during all lines of therapy in the metastatic setting will be described. The 2-year survival rate and median OS with interquartile range (IQR) for third-line therapy will be calculated. HRU data and costs during third-line therapy will be collected.